Healthcare
Korean AI drug developer secures $14m Series B
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech...
China biotech player InxMed raises $19m
Ennovation Ventures, a Chinese life sciences and healthcare-focused investor, and China Growth Capital have led a RMB130 million ($19 million) round for local biotech developer InxMed.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
Vision Fund leads $100m Series C for Singapore-founded Biofourmis
SoftBank Vision Fund has led a $100 million Series C round for Biofourmis, a Singapore founded and now US-based operator of a health analytics platform.
Deal focus: Creador scores as India pharma heats up
Creador's $34 million investment in packaging supplier Shriji Polymers represents an indirect bet on India's growing pharmaceutical industry. Product development and capacity expansion are priorities
Deal focus: Shukun stands out from the crowd
Shukun sought to differentiate itself from other Chinese artificial intelligence medical imaging start-ups by focusing on heart rather than lung conditions, but a COVID-19 diagnosis solution has given the company real traction
Chinese drug developer Adlai Nortye raises $100m Series C
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
Carlyle invests $260m in China's Salubris Pharmaceutical
The Carlyle Group has paid about $260 million for a 5% stake in Shenzhen-listed Salubris Pharmaceutical.
Creador invests $34m in India's Shriji Polymers
Creador has invested INR2.5 billion ($34 million) in Shriji Polymers India, a manufacturer of plastic pharmaceuticals packaging, taking a significant minority stake and providing an exit for Tata Capital.
Qiming joins Series B for Chinese AI diagnosis player
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the medical imaging diagnosis, has raised RMB200 million in the third tranche of Series B round.
BGH, OTPP reengage with New Zealand's Abano
BGH Capital and Ontario Teachers’ Pension Plan (OTPP), which recently terminated an acquisition of New Zealand dentistry chain Abano, have renewed their bid at a lower price.
RA Capital leads round for China's Connect Biopharma
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
Blackstone agrees $2.3b carve-out from Japan's Takeda
Japan’s Takeda Pharmaceutical has agreed to sell a portfolio of over-the-counter (OTC) medicines and health products to The Blackstone Group for JPY242 billion ($2.3 billion).
Q&A: ChrysCapital Partners' Sanjay Kukreja
Sanjay Kukreja, managing partner at India-focused ChrysCapital Partners, discusses timing, healthcare, technology, and why it makes sense to back entrepreneurs you’ve backed before
China insurance tech platform Waterdrop receives $230m
Shuidi, a China-based insurance technology platform also known as Waterdrop, has raised $230 million in Series D funding jointly led by Tencent Holdings and Swiss Re Group. Existing investors IDG Capital and Wisdom Choice Global Fund re-upped.
China drug developer Dizal raises $100m
Chinese drug developer Dizal Pharmaceuticals has raised a $100 million round led by Lilly Asia Ventures, with participation from Sequoia Capital, Trinity Innovation Fund, and Wuxi NewForce Fund.
India pharma: The pills are popping
India’s pharmaceuticals industry is thriving on the macro ills of the day. Private equity is well placed to benefit, but the opportunity set is no secret
Reliance unit acquires India's Netmeds
Reliance Retail Ventures (RRVL), a company associated with Jio Platforms, has acquired Indian VC-backed drug marketplace Netmeds.
Xiaomi-backed Soocas raises $25m pre-IPO round
Soocas, a Shenzhen-based electric toothbrush maker backed by smart phone maker Xiaomi has raised a RMB175 million ($25 million) pre-IPO round led by Grand Flight Investment Management.
Hillhouse invests $830m in China's JD Health
Hillhouse Capital has agreed to invest $830 million in JD Health, the healthcare unit of Chinese e-commerce giant JD.com, which will remain the majority shareholder.
Baring Asia mulls challenging for Japan's Nichii Gakkan
Baring Private Equity Asia is poised to formally enter the bidding for Tokyo-listed aged care provider Nichii Gakkan, having approached certain shareholders regarding a JPY146 billion ($1.38 billion) deal.
Centurium buys Beijing children's hospital
Centurium Capital has acquired a controlling stake in Beijing Jingdu Children’s Hospital, which claims to be the largest privately-owned children’s hospital in China, for approximately $150 million.
China medical device player Hanyu Medical secures $72m
China-based medical devices manufacturer Hanyu Medical has raised a RMB500 million ($72 million) Series D co-led by HighLight Capital, CPE (formerly known as CITIC Private Equity), and Yingke Private Equity.
Japan's ACA exits aged care business
Tokyo-listed healthcare provider Solasto will acquire 100% of Japan Elderly Care Service for JPY2.3 billion ($22 million), providing an exit for local private equity firm ACA Investments.